Keryx Biopharmaceuticals (KERX) Soars On Baupost Deal

Baupost Group, the hedge fund managed by acclaimed value investor Seth Klarman, has once again boosted its holding in Keryx Biopharmaceuticals. [klarman] [dalio] Today, Keryx announced that it has entered into an agreement with funds managed by Baupost Group, L.L.C, to raise $125 million through the private placement of Convertible Senior Notes, due 2020. [drizzle]Keryx Biopharmaceuticals is focused on bringing innovative therapies to market for people with renal disease. Baupost has held a position in the company since May 2014. And Klarman has been steadily increasing his position in Keryx since the second quarter of last year. After buying an initial stake of 9.15…